Actively Recruiting
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Led by Zhejiang Cancer Hospital · Updated on 2026-05-11
25
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, single-center, open-label, single-arm clinical trial to assess the safety and efficacy of umbilical cord blood in cancer treatment-induced thrombocytopenia (CTIT) patients. It plans to recruit subjects aged 12 to 65 years old with CTIT. The study involves intravenous infusion of umbilical cord blood, with platelet transfusion as supportive therapy if necessary. The trial consists of three phases: screening (baseline assessments and enrollment), treatment (umbilical cord blood infusion), and follow-up (blood routine tests at Days 3, 7, 14, and 28 post-treatment to record platelet counts, first response time, maximum and minimum values, and calculate efficacy rates while observing changes in thrombocytopenia grading). A total of 25 subjects will be enrolled, and they will undergo evaluation for safety and efficacy based on treatment-related adverse events, GVHD incidence, and hematological improvements.
CONDITIONS
Official Title
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 12 to 65 years at the time of informed consent, regardless of gender
- Diagnosed with cancer treatment-induced thrombocytopenia (CTIT) with platelet count below 100 x 10^9/L
- Previous exposure to chemotherapy, tumor-targeted therapy, immunotherapy, or other anti-tumor drugs causing thrombocytopenia
- Gradual improvement or normalization of platelet count after stopping the offending drug
- May have bleeding symptoms such as petechiae, purpura, unexplained nosebleeds, or severe bleeding
- No significant liver or kidney impairment: ALT and AST ≤ 2.5 times upper limit of normal, creatinine and blood urea nitrogen ≤ 1.25 times upper limit of normal
- Karnofsky Performance Status score of 60 or higher and ECOG performance status 0 to 2
- Estimated life expectancy of more than 3 months
You will not qualify if you...
- Thrombocytopenia caused by other diseases like aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenia, hypersplenism, or bone marrow infiltration by tumor cells
- Use of non-anti-tumor drugs known to cause thrombocytopenia
- Pseudothrombocytopenia caused by EDTA anticoagulant
- Uncontrolled cancer, high blood pressure, or diabetes
- Active infections such as HIV, hepatitis B or C, or syphilis
- Poor compliance with study requirements
- Known allergy or sensitivity to umbilical cord blood or related products
- Participation in another clinical trial within one month before enrollment
- Any other condition that the investigator judges as unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Hematology, Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
X
Xiaolin Yuan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here